Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ULK1 | O75385 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12994066 | 0.82 | GRM4 (0.59) | GRM4TNFNPC1RAB9ANPSR1 | |
| SCHEMBL21203658 | 0.82 | GRM4 (0.59) | GRM4TNFNPC1RAB9ANPSR1 | |
| SCHEMBL20551117 | 0.82 | TNF (0.51) | GRM4TNFNPC1RAB9ANPSR1 | |
| SCHEMBL20551109 | 0.81 | TNF (0.50) | GRM4TNFNPC1RAB9ANPSR1 | |
| SCHEMBL18796078 | 0.80 | NPSR1 (0.49) | GRM4TNFNPC1RAB9ANPSR1 | |
| SCHEMBL30099860 | 0.80 | NPSR1 (0.49) | GRM4TNFNPC1RAB9ANPSR1 | |
| SCHEMBL22229502 | 0.80 | KDR (0.54) | GRM4TNFNPC1RAB9ANPSR1 | |
| SCHEMBL20552020 | 0.80 | KDR (0.57) | GRM4TNFNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22229531 | 0.80 | CYP1A2 (0.57) | GRM4TNFNPC1RAB9ANPSR1 | |
| SCHEMBL1702408 | 0.80 | IGF1R (0.57) | GRM4TNFNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231607-A1 | TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-07-23 | — | — | US | claimed |
| EP-3618632-A1 | TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES | Bayer Aktiengesellschaft (DE) | 2020-03-11 | — | — | EP | claimed |
| WO-2018202706-A1 | TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | WO | claimed |
| US-20200231607-A1 | TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-07-23 | — | — | US | disclosed |
| EP-3618632-A1 | TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES | Bayer Aktiengesellschaft (DE) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018202706-A1 | TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231607-A1 | TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES | PIK3C3, ERG28, DDT | GRM4 2291/4885TNF 4347/4885NPC1 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.